GenSpera, Inc. (GenSpera) is an early-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including liver, brain, prostate, renal and other cancers. A prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. The company's technology platform combines a plant-derived cytotoxin with a prodrug delivery system that focuses on the release of the drug within the tumor. Its cancer prodrugs provide a focused therapeutic approach to a range of solid tumors with fewer side effects than those related to current chemotherapy treatments. The Company's lead drug candidate is mipsagargin. The Company's other prodrug candidates include G-114, G-115 and G-301.